Entero Healthcare Solutions rises 29.4% from October close

Entero Healthcare Solutions Limited gained 29.4% from its ₹1,575.20 close on October 30, 2026, to ₹1,900.40 on November 6, supported by reported Q2 FY27 net profit growth of 44.1% year-on-year to ₹46 crore and revenue growth of 32.9%.

How much did Entero rise after October 30?

Entero rose 29.4% between the October 30 close and the November 6 close, rather than recording that full increase during October alone. The stock closed at ₹1,575.20 on October 30 and at ₹1,900.40 on November 6, a gain of ₹325.20 over the period.

Available late-October data show a more gradual move before the early-November rally. The share closed at ₹1,468.40 on October 23, rose to ₹1,578.20 on October 27, and ended October 30 at ₹1,575.20. This sequence is important because the widely discussed near-30% advance spans the transition from October into November.

What were Entero's Q2 FY27 results?

Entero reported Q2 FY27 net profit growth of 44.1% year-on-year to ₹46 crore, while revenue increased 32.9%. These reported figures coincided with the period in which the share accelerated after the October 30 close.

The available discussion does not provide absolute revenue, margin details, cash-flow figures, or management guidance. As a result, the reported profit and revenue growth establish the main financial backdrop for the share-price move, but do not by themselves explain every trading-day fluctuation.

For investors assessing the results, the key disclosed comparison is the gap between profit growth and revenue growth. The context indicates that net profit increased faster than revenue, though it does not provide enough information to identify the specific operational or cost factors behind that outcome.

How did Entero trade in early November?

Entero closed at ₹1,754.10 on November 5 and then gained ₹146.30, or 8.34%, to close at ₹1,900.40 on November 6. On November 6, the share traded between an intraday low of ₹1,761.30 and a high of ₹1,936.60.

The November 6 intraday high of ₹1,936.60 was reported as a new 52-week high at that point. Separate market snapshots dated November 8 reported prices ranging from ₹2,025.40 to ₹2,065.00, with ₹2,069.00 cited as the day high and 52-week high. Those later snapshots show that the stock remained active after the November 6 rise.

The supplied price references differ across timestamps and exchanges, so comparisons should be made using the stated date and closing basis. The clearest measured rally in the available data remains the move from the October 30 NSE close of ₹1,575.20 to the November 6 NSE close of ₹1,900.40.

What price levels and broker target are in focus?

Entero reached ₹1,936.60 intraday on November 6, while ICICI Securities issued a buy recommendation with a ₹2,100 target in a research report dated November 6, 2026. The target was above the reported ₹1,900.40 November 6 close.

The stock's 52-week low is reported differently in the supplied snapshots, including ₹944.00, ₹953.00, ₹986.50 and ₹1,089.30 for different reference dates and sources. The most recent November 8 snapshot cited a 52-week range of ₹944.00 to ₹2,069.00, while the November 6 trading data identified ₹1,936.60 as the then-new high.

The context also cited a market capitalisation of ₹7,653 crore and a P/E of 53.5 when the share last traded at ₹1,754. These valuation references are point-in-time figures and should be read alongside the price date stated in each market snapshot.

Conclusion

Entero's reported 29.4% move was principally an early-November advance following the October 30 close, not an October-only rally. The rise occurred alongside reported Q2 FY27 net profit growth of 44.1% to ₹46 crore and revenue growth of 32.9%, with the share closing at ₹1,900.40 on November 6 after an 8.34% one-day gain.

Investors can watch whether the share sustains levels near the reported November highs and how it trades relative to ICICI Securities' ₹2,100 target. Further clarity on revenue, margins, cash flow and management outlook would be needed to assess whether the reported quarterly growth can continue.